Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy

Empagliflozin, a sodium –glucose co-transporter 2 inhibitor (SGLT2i), has been reported to significantly reduce the risk of heart failure in multiple clinical studies. However, the underlying mechanisms remain ...

Source: Diabetology and Metabolic Syndrome - May 6, 2023 Category: Endocrinology Authors: Lin Zhang, Heming Zhang, Xiuzhu Xie, Ruping Tie, Xiaolin Shang, Qianqian Zhao, Junjie Xu, Liyuan Jin, Jinying Zhang and Ping Ye Tags: Research Source Type: research